Unclear
RCC SBRT local control
TL;DR100% local control at 5 years for primary RCC treated with SBRT, per a conference tweet with no denominator.
The RT-relevant gap is technique: no dose, fractionation, or tumor-size cap is in the source, and those are what determine whether a primary-RCC SBRT local-control figure transfers to a reader's practice. Without them this does not move the SBRT vs partial nephrectomy or ablation decision.
6 details
Not reported in source. The tweet gives no phase, sample size, sites, or accrual period; the underlying series cannot be identified from the text provided.
No dose, fractionation, or technique reported in source. Primary-RCC SBRT regimens vary widely across published series, so the local-control claim cannot be attributed to a specific regimen.
100% local control at 5 years is the only figure in the source. No denominator, no confidence interval, and no local-control definition accompany it.
Single social-media claim without a linked abstract, figure, or registration. Local control alone omits the renal-function and cancer-specific-survival endpoints that gate modality choice in primary RCC.
Single tweet with a bare local-control percentage; no N, design, dose, or follow-up definition to classify against. Underlying series not identifiable from source.
- Which series does this 100% 5-yr local control come from
- SBRT vs partial nephrectomy or thermal ablation in operable primary RCC
- Renal function preservation after primary-RCC SBRT
📚 Sources · 🐦 1 tweet
These results are so impressive!! 💯 local control at 5 years for RCC treated with SBRT@DrRanaMcKay @AdityaBagrodia @DrTylerStewart @DrYukselUrun @OncoAlert https://t.co/fUB3airM5g
— Tyler Seibert MD PhD (@TylerSbrt) May 17, 2026
DIREKHT
ForResected HNSCC, post-operative RT candidates
TL;DRContralateral neck sparing and 56 Gy primary CTV de-escalation in selected post-op HNSCC; no effect sizes reported in source tweets.
The RT-relevant lever is target volume plus dose, not systemic therapy: contralateral neck sparing in a selected subgroup and a 56 Gy primary CTV. Both would move the elective-volume and dose-de-escalation decision in post-op HNSCC, but the source gives no control or toxicity numbers to weigh them against.
6 details 5 trials watching
Two de-escalation levers: contralateral neck sparing in a specified subgroup, and primary CTV dose reduced to 56 Gy. Fractionation, high-risk CTV dose, and elective nodal dose are not reported in source.
Post-operative HNSCC. The contralateral-sparing subset is described only as a "specified group"; the criteria are not in source.
Source is a single third-party commentary tweet. No design, N, endpoints, or effect sizes reported; the linked detail was not captured.
Source is a commentary tweet with no design, N, endpoints, or effect sizes. Nothing reported that supports classifying the result.
- Which subgroup safely tolerates contralateral neck sparing n=396 · primary completion 2027-12 · randomised omission of nodal RT in pN0-N1 oral cavity
- Locoregional control with 56 Gy vs standard post-op dose recruiting The Efficacy and Safety of De-escalated Postoperative Radiotherapy in Locally Advanced HNSCC With pCR/MPR Phase NAn=23 · primary completion 2027-04 · PORT 50 Gy vs standard 60 Gy after pCR/MPRrecruiting Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer Phase 2n=150 · primary completion 2028-12 · risk-stratified de-escalated adjuvant IMRT post-TORS
- Late toxicity and swallowing outcomes after volume plus dose de-escalation n=33 · primary completion 2026-01 · reduced-dose RT post-TORS, long-term toxicity focusrecruiting Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial Phase 2n=90 · primary completion 2026-09 · QoL primary: omit pN0 neck RT vs full volume
📚 Sources · 🐦 1 tweet
There are tremendous opportunities to improve post-operative radiotherapy in HNSCC. The DIREKHT trial is an excellent example of such work, in which they spared the contralateral neck in a specified group of patients and/or reduced the primary CTV dose to 56 Gy.
— David Sher (@DavidSherMD) May 16, 2026
The details… https://t.co/7W84LYIofR